• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2020 o Market outlook: Forecast for 2020 - 2025 • Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Route of administration o Market segments o Comparison by Route of administration o Parenteral - Market size and forecast 2020-2025 o Oral - Market size and forecast 2020-2025 o Vaginal - Market size and forecast 2020-2025 o Market opportunity by Route of administration • Customer landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2020-2025 o Europe - Market size and forecast 2020-2025 o Asia - Market size and forecast 2020-2025 o ROW - Market size and forecast 2020-2025 o Key leading countries o Market opportunity By Geographical Landscape o Market drivers o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o AbbVie Inc. o Aurobindo Pharma Ltd. o Dr. Reddys Laboratories Ltd. o Ferring B.V. o Lupin Ltd. o Merck KGaA o Mylan NV o Novartis AG o Sanofi SA o Takeda Pharmaceutical Co. Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2020 - 2025 ($ million) • 13: Global market: Year-over-year growth 2020 - 2025 (%) • 14: Five forces analysis 2020 & 2025 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2020 • 21: Route of administration - Market share 2020-2025 (%) • 22: Comparison by Route of administration • 23: Parenteral - Market size and forecast 2020-2025 ($ million) • 24: Parenteral - Year-over-year growth 2020-2025 (%) • 25: Oral - Market size and forecast 2020-2025 ($ million) • 26: Oral - Year-over-year growth 2020-2025 (%) • 27: Vaginal - Market size and forecast 2020-2025 ($ million) • 28: Vaginal - Year-over-year growth 2020-2025 (%) • 29: Market opportunity by Route of administration • 30: Customer landscape • 31: Market share By Geographical Landscape 2020-2025 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2020-2025 ($ million) • 34: North America - Year-over-year growth 2020-2025 (%) • 35: Europe - Market size and forecast 2020-2025 ($ million) • 36: Europe - Year-over-year growth 2020-2025 (%) • 37: Asia - Market size and forecast 2020-2025 ($ million) • 38: Asia - Year-over-year growth 2020-2025 (%) • 39: ROW - Market size and forecast 2020-2025 ($ million) • 40: ROW - Year-over-year growth 2020-2025 (%) • 41: Key leading countries • 42: Market opportunity By Geographical Landscape ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: AbbVie Inc. - Overview • 50: AbbVie Inc. - Product and service • 51: AbbVie Inc. - Key offerings • 52: AbbVie Inc. - Key customers • 53: AbbVie Inc. - Segment focus • 54: Aurobindo Pharma Ltd. - Overview • 55: Aurobindo Pharma Ltd. - Product and service • 56: Aurobindo Pharma Ltd. - Key offerings • 57: Aurobindo Pharma Ltd. - Key customers • 58: Aurobindo Pharma Ltd. - Segment focus • 59: Dr. Reddys Laboratories Ltd. - Overview • 60: Dr. Reddys Laboratories Ltd. - Business segments • 61: Dr. Reddys Laboratories Ltd. - Key offerings • 62: Dr. Reddys Laboratories Ltd. - Key customers • 63: Dr. Reddys Laboratories Ltd. - Segment focus • 64: Ferring B.V. - Overview • 65: Ferring B.V. - Product and service • 66: Ferring B.V. - Key offerings • 67: Ferring B.V. - Key customers • 68: Ferring B.V. - Segment focus • 69: Lupin Ltd. - Overview • 70: Lupin Ltd. - Product and service • 71: Lupin Ltd. - Key offerings • 72: Lupin Ltd. - Key customers • 73: Lupin Ltd. - Segment focus • 74: Merck KGaA - Overview • 75: Merck KGaA - Business segments • 76: Merck KGaA - Key offerings • 77: Merck KGaA - Key customers • 78: Merck KGaA - Segment focus • 79: Mylan NV - Overview • 80: Mylan NV - Business segments • 81: Mylan NV - Key offerings • 82: Mylan NV - Key customers • 83: Mylan NV - Segment focus • 84: Novartis AG - Overview • 85: Novartis AG - Business segments • 86: Novartis AG - Key offerings • 87: Novartis AG - Key customers • 88: Novartis AG - Segment focus • 89: Sanofi SA - Overview • 90: Sanofi SA - Business segments • 91: Sanofi SA - Key offerings • 92: Sanofi SA - Key customers • 93: Sanofi SA - Segment focus • 94: Takeda Pharmaceutical Co. Ltd. - Overview • 95: Takeda Pharmaceutical Co. Ltd. - Product and service • 96: Takeda Pharmaceutical Co. Ltd. - Key offerings • 97: Takeda Pharmaceutical Co. Ltd. - Key customers • 98: Takeda Pharmaceutical Co. Ltd. - Segment focus • 99: Currency conversion rates for US$ • 100: Research Methodology • 101: Validation techniques employed for market sizing • 102: Information sources • 103: List of abbreviations

AbbVie Inc., Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Ferring B.V., Lupin Ltd., Merck KGaA, Mylan NV, Novartis AG, Sanofi SA, Takeda Pharmaceutical Co. Ltd.